{
}
Deshawn “DJ” Chow, a 19-year-old with sickle cell disease, received Casgevy, the first approved CRISPR-based treatment, after a year of waiting. Despite its promise, the rollout has been slow due to manufacturing complexities and insurance hurdles, with only a few patients treated since its December 2023 approval. Chow hopes the therapy will alleviate his pain and allow him to pursue activities like snowboarding, reflecting a cautious optimism for the future of sickle cell treatments.
CRISPR Therapeutics has faced a challenging market, with shares down 23% year-to-date despite recent regulatory approvals for its gene-editing medicine, Casgevy, which treats sickle cell disease and beta-thalassemia. The Biden administration's new Medicaid initiative aims to improve access to Casgevy, potentially expanding its market significantly. With a projected peak annual sales exceeding $2.2 billion, the company is well-positioned for future growth, although it currently reports minimal revenue.
CRISPR Therapeutics has faced a 23% decline in stock value this year despite recent regulatory approvals for its gene-editing medicine, Casgevy, which treats sickle cell disease and beta-thalassemia. The high cost of $2.2 million per treatment poses accessibility challenges, but a new U.S. government plan aims to help Medicaid patients afford it, potentially expanding access for many. However, the company reported only $1.6 million in revenue in the first nine months, indicating slow uptake of Casgevy.
CRISPR Therapeutics has received a Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA for its cell therapy CTX112, aimed at treating relapsed or refractory B-cell malignancies. This designation allows for a potentially expedited approval process, offering financial flexibility and a simpler manufacturing approach. While the new development is promising, the success of CTX112 still hinges on convincing safety and efficacy data in clinical trials.
CRISPR Therapeutics has received a Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA for its cell therapy CTX112, aimed at treating relapsed or refractory B-cell malignancies. This designation allows for expedited development and potential early revenue generation, enhancing the company's financial flexibility. The off-the-shelf manufacturing approach of CTX112 could lead to more consistent patient responses, positioning CRISPR favorably for future growth despite inherent clinical trial risks.
CRISPR Therapeutics insiders have sold 50,382 shares worth $2.74 million in the last 90 days, with insiders owning 4.10% of the company. Institutional investors hold 69.20% of the stock, while analysts maintain a "Hold" rating, with a consensus target price of $77.93. The company's recent earnings report showed a loss of $1.01 per share, exceeding expectations, but revenue fell short at $0.60 million.
Larson Financial Group LLC increased its stake in CRISPR Therapeutics by 95.5% in Q2, now holding 565 shares valued at $31,000. Other institutional investors also made significant investments, with ownership among them at 69.20%. CRISPR Therapeutics, focused on gene-editing for serious diseases, recently hit a 52-week low of $40.61, with analysts giving it a consensus "Hold" rating and an average price target of $77.93.
The biotech sector is witnessing renewed interest in gene therapies, particularly following recent FDA approvals. Companies like Sarepta Therapeutics, CRISPR Therapeutics, and Voyager Therapeutics are positioned for growth in 2025, with Sarepta's Elevidys leading the way as the first gene therapy for Duchenne muscular dystrophy. The company is also expanding its pipeline with new treatments for other neuromuscular disorders.
CRISPR Therapeutics AG (NASDAQ:CRSP) experienced a 6.4% decline in short interest in November, totaling 18,150,000 shares. Analysts have mixed ratings, with a consensus "Hold" and a target price of $77.93, while CEO Samarth Kulkarni sold 30,000 shares, reducing his stake by 13.24%. The company reported a quarterly EPS of ($1.01), surpassing estimates, but revenue fell short at $0.60 million.
Crispr Therapeutics (CRSP) is experiencing above-normal call volume, indicating bullish sentiment, with 5,198 calls traded—1.3 times the expected amount. Implied volatility has risen over 3 points to 55.13%, with the Jan-25 50 calls and Dec-24 47 calls being the most active. The Put/Call Ratio stands at 0.20, and earnings are anticipated on February 19th.
CRISPR Therapeutics AG
Companies
| Symbol | CRSP |
| Name | CRISPR Therapeutics AG |
| Currency | USD |
| Sector | Health Care |
| IndustryGroup | Pharmaceuticals, Biotechnology & Life Sciences |
| Industry | Biotechnology |
| Market | NASDAQ Global Select |
| Country | Switzerland |
| State | |
| City | Zug |
| Zipcode | 6300 |
| Website | http://www.crisprtx.com |
The information provided herein is generated by experimental artificial intelligence and is for informational purposes only.
new crispr treatment for sickle cell disease faces slow rollout challenges
United States Dollar
Vertex Pharmaceuticals Inc
bluebird bio, Inc.
CRISPR Therapeutics AG
USA
Edward Donnell Ivy
David Jacobsohn
Leo Wang
Show more
12:30 23.12.2024
CRISPR Therapeutics gains momentum with new Medicaid plan for gene therapy access
United States Dollar
Vertex Pharmaceuticals Inc
bluebird bio, Inc.
CRISPR Therapeutics AG
SAU
USA
BHR
GBR
Show more
18:25 22.12.2024
CRISPR Therapeutics gains momentum with Medicaid plan for gene-editing treatment
United States Dollar
Vertex Pharmaceuticals Inc
CRISPR Therapeutics AG
SAU
BHR
GBR
USA
Joe Biden
Show more
18:25 22.12.2024
crispr therapeutics gains momentum with new fda designation for cell therapy
Vertex Pharmaceuticals Inc
Apple Inc.
NVIDIA Corporation
Netflix, Inc.
CRISPR Therapeutics AG
USA
Alex Carchidi
Show more
15:30 20.12.2024
crispr therapeutics gains momentum with new fda designation for cell therapy
15:30 20.12.2024
insider sales and hedge fund activity at crispr therapeutics raise eyebrows
15:09 20.12.2024
crispr therapeutics shares hit new low amid mixed analyst ratings
12:18 19.12.2024
promising gene therapy stocks to watch in the evolving biotech landscape
14:59 17.12.2024
crispr therapeutics experiences drop in short interest and mixed analyst ratings
04:20 17.12.2024
Crispr Therapeutics sees bullish call volume ahead of earnings report
21:25 16.12.2024
Trending
Subcategory
Corporate News
Industry Trends
Cryptocurrency Trends
Emerging Startups
Venture Capital Investments
Funding Rounds & Investments
AI Innovations
Startups & Entrepreneurship
Crypto Adoption and Integration
Fintech Startups
AI Applications
Retail and Consumer Goods
Crypto Policies and Governance
Product Launches
Workplace Trends
Central Banks and Digital Currencies
IPOs of Tech Companies
Economic Indicators
Market Analysis and Predictions
IPOs & SPACs
Countries:
Companies:
Apple Inc.
Nvidia Corporation
DEUTSCHE BANK AG
EVOLUTION JAPAN Securities Co. Ltd.
Alphabet Inc.
Marvell Technology Inc.
Playtika Holding Corp.
Colugo Systems Ltd.
Gemini Trust Company LLC
Circle Internet Financial Inc.
Citigroup Inc.
Bank of America Corporation
Sony Corporation
Zero Networks Ltd.
Ecom Express Ltd.
Minebea Mitsumi Inc.
VOLKSWAGEN AG
Currencies:
People: